Overview

A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2023-12-06

Target enrollment:

Participant gender:

Summary

This study is a single-center, open Phase I study, to observe the effectiveness and safety of CT103A combined with different doses of Selinexor in patients with relapsed/refractory extramedullary multiple myeloma, and the pharmacokinetics of Selinexor and CT103A Kinetic and pharmacodynamic characteristics.

Phase:

Phase 1

Details

Lead Sponsor:

Huazhong University of Science and Technology

Collaborator:

Nanjing IASO Biotherapeutics Co.,Ltd